These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12209028)

  • 1. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition.
    Maddison P
    Rheumatology (Oxford); 2002 Sep; 41(9):965-71. PubMed ID: 12209028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
    Gliddon AE; Doré CJ; Black CM; McHugh N; Moots R; Denton CP; Herrick A; Barnes T; Camilleri J; Chakravarty K; Emery P; Griffiths B; Hopkinson ND; Hickling P; Lanyon P; Laversuch C; Lawson T; Mallya R; Nisar M; Rhys-Dillon C; Sheeran T; Maddison PJ
    Arthritis Rheum; 2007 Nov; 56(11):3837-46. PubMed ID: 17968938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders.
    Plosker GL; Sorkin EM
    Drugs; 1994 Aug; 48(2):227-52. PubMed ID: 7527326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR; Jarvis B
    Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure.
    Sedman AJ; Posvar E
    Angiology; 1989 Apr; 40(4 Pt 2):360-9. PubMed ID: 2539762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors?
    Malik RA
    Ann Med; 2000 Feb; 32(1):1-5. PubMed ID: 10711571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis.
    de Vries-Bouwstra JK; Allanore Y; Matucci-Cerinic M; Balbir-Gurman A
    J Rheumatol; 2020 Feb; 47(2):249-254. PubMed ID: 31043545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients.
    Moinzadeh P; Riemekasten G; Siegert E; Fierlbeck G; Henes J; Blank N; Melchers I; Mueller-Ladner U; Frerix M; Kreuter A; Tigges C; Lahner N; Susok L; Guenther C; Zeidler G; Pfeiffer C; Worm M; Karrer S; Aberer E; Bretterklieber A; Genth E; Simon JC; Distler JH; Hein R; Schneider M; Seitz CS; Herink C; Steinbrink K; Sárdy M; Varga R; Mensing H; Mensing C; Lehmann P; Neeck G; Fiehn C; Weber M; Goebeler M; Burkhardt H; Buslau M; Ahmadi-Simab K; Himsel A; Juche A; Koetter I; Kuhn A; Sticherling M; Hellmich M; Kuhr K; Krieg T; Ehrchen J; Sunderkoetter C; Hunzelmann N;
    J Rheumatol; 2016 Jan; 43(1):66-74. PubMed ID: 26568599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
    Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
    Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.
    White B; Bauer EA; Goldsmith LA; Hochberg MC; Katz LM; Korn JH; Lachenbruch PA; LeRoy EC; Mitrane MP; Paulus HE
    Arthritis Rheum; 1995 Mar; 38(3):351-60. PubMed ID: 7880189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinapril: a double-blind, placebo-controlled trial in essential hypertension.
    Maclean D
    Angiology; 1989 Apr; 40(4 Pt 2):370-81. PubMed ID: 2650581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical restenosis trials: a perspective from the pharmaceutical industry.
    Uprichard AC; Texter M; Canter D
    Circulation; 1992 Apr; 85(4):1636-7. PubMed ID: 1555305
    [No Abstract]   [Full Text] [Related]  

  • 13. Vasospasmolytic therapy in patients with SSC.
    Jünger M; Schlez A; Klyscz T; Steins A; Hahn M
    Adv Exp Med Biol; 1999; 455():305-7. PubMed ID: 10599360
    [No Abstract]   [Full Text] [Related]  

  • 14. Quinapril in chronic heart failure.
    Northridge DB; Dargie HJ
    Am J Hypertens; 1990 Nov; 3(11):283S-287S. PubMed ID: 2261147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin-converting enzyme, quinapril, in treating chronic cardiac failure].
    Gadzhiev AN
    Ter Arkh; 2003; 75(1):51-5. PubMed ID: 12652958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for ACE inhibition as an anti-ischaemic therapy.
    Pepine CJ
    Eur Heart J; 1998 Jul; 19 Suppl G():G34-40. PubMed ID: 9717054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure.
    Northridge DB; Rose E; Raftery ED; Lahiri A; Elder AT; Shaw TR; Henderson E; Dargie HJ
    Eur Heart J; 1993 Mar; 14(3):403-9. PubMed ID: 8458362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
    Torsello A; Locatelli V; Cella SG; Sanguini AM; Berti F
    J Endocrinol Invest; 2003 Jan; 26(1):79-83. PubMed ID: 12602539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
    Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
    Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.